Deeply undervalued · +42.6% margin of safety
Market outside MC distributionMarket €117.80 vs DCF €205.27 (post-governance, pre-gov €216.07). Even at the 5th-percentile Monte Carlo outcome (€166.76), intrinsic value exceeds today's price by 42%.
What it sells, where it sells
Operating segments — FY25 revenue €5.66B
Modeled as one consolidated segment in the DCF. Lifecycle Service is the margin engine.
Country mix (revenue-weighted)
Quality profile & the two-sided argument
A five-axis read on the DCF's load-bearing assumptions, plus the bull-vs-bear case distilled into anchor bullets.
Quality snowflake (each axis 0–6)
The two-sided case
- Cleanest setup in the watchlist. €117.80 market vs €205.27 DCF = +74% MoS. Q1 EPS softness (-9.6%) is FX translation + Ingeniq 100bp transition drag, not structural. Market is pricing event noise as if it were thesis-killing.
- Backlog €4.3B = ~9 months forward visibility, mechanically locked. Q1 order intake +5.3% to €1.51B; book-to-bill 1.10; FY26 guidance reaffirmed (3-5% rev growth, EBITDA 10.7-11.1%, ROCE 19-20%). Demand signal is not breaking.
- Fortress balance sheet underwrites the cycle. €548M net cash, zero financial debt, equity ratio 42%, €888M undrawn lines, ICR 52× → synthetic Aaa. Cyclical pressure cannot bend this company structurally.
- Aluminum-can transition is a TAILWIND, not a risk. Krones leads global aluminum line conversion; Coca-Cola/Pepsi accelerated aluminum capex creates a multi-year replacement cycle Chinese competitors cannot yet supply at Krones' integration quality.
- Lowest governance discount in the EU set (0.05). Kronseder family 51.9% pool with 75-year track record of pro-minority alignment: flat share count, 25-30% payout, ROCE expanding 10%→19.1% in 5y, family vehicle (Schawei) net buyer at recent prices.
- PET → aluminum transition stalls If consumer or regulatory pressure on aluminum eases, the line-conversion replacement-cycle thesis softens; growth drops to 2-3% explicit period.
- Emerging market FX ~30% revenue from Mexico/India/MEA; sustained EM FX weakness compresses EUR translation (already visible in Q1 2026 -2.2% reported vs +1.4% cc).
- Cyclical machinery downturn If beverage capex pauses 2027+, backlog burns down and Y3-5 growth disappoints. Mitigated by €548M net cash absorbing any single-cycle slowdown.
- Commoditization by Chinese competitors Substack bear thesis: lower-end PET/can lines compress margin back to 6-7% by Y10; service annuity cannibalized by 3rd-party retrofits.
- Kronseder family 51.9% control 75-year pro-minority track record; 2023 DAX-family removal over C.10 committee form is governance optics, not value extraction. Priced via 0.05 haircut.
Thesis & open questions
Investment thesis
- Cleanest setup in the watchlist. €117.80 market vs €205.27 DCF = +74% MoS. Q1 EPS softness (-9.6%) is FX translation + Ingeniq 100bp transition drag, not structural. Market is pricing event noise as if it were thesis-killing.
- Backlog €4.3B = ~9 months forward visibility, mechanically locked. Q1 order intake +5.3% to €1.51B; book-to-bill 1.10; FY26 guidance reaffirmed (3-5% rev growth, EBITDA 10.7-11.1%, ROCE 19-20%). Demand signal is not breaking.
- Fortress balance sheet underwrites the cycle. €548M net cash, zero financial debt, equity ratio 42%, €888M undrawn lines, ICR 52× → synthetic Aaa. Cyclical pressure cannot bend this company structurally.
- Aluminum-can transition is a TAILWIND, not a risk. Krones leads global aluminum line conversion; Coca-Cola/Pepsi accelerated aluminum capex creates a multi-year replacement cycle Chinese competitors cannot yet supply at Krones' integration quality.
- Lowest governance discount in the EU set (0.05). Kronseder family 51.9% pool with 75-year track record of pro-minority alignment: flat share count, 25-30% payout, ROCE expanding 10%→19.1% in 5y, family vehicle (Schawei) net buyer at recent prices.
Key debates
Risks to thesis
If consumer or regulatory pressure on aluminum eases, the line-conversion replacement-cycle thesis softens; growth drops to 2-3% explicit period.
~30% revenue from Mexico/India/MEA; sustained EM FX weakness compresses EUR translation (already visible in Q1 2026 -2.2% reported vs +1.4% cc).
If beverage capex pauses 2027+, backlog burns down and Y3-5 growth disappoints. Mitigated by €548M net cash absorbing any single-cycle slowdown.
Substack bear thesis: lower-end PET/can lines compress margin back to 6-7% by Y10; service annuity cannibalized by 3rd-party retrofits.
75-year pro-minority track record; 2023 DAX-family removal over C.10 committee form is governance optics, not value extraction. Priced via 0.05 haircut.
Top 10 customers ~40% revenue, spread across Coca-Cola / Pepsi / AB InBev / Heineken bottlers — diversified by geography and product line.
10-year forecast
Revenue + FCFF on the left axis; operating margin on the right axis.
Monte Carlo distribution
Mean €204.25 ± €23.87 · P(intrinsic < market) = 0.0% · 1000 iterations (0 failed).
- terminal_growth (0.0240) >= risk_free_rate (0.0240); Damodaran's stable-growth ceiling is the risk-free rate
Cost of capital build
| Risk-free rate | 0.22% | implied from CE − β·(ERP+CRP) |
| Mature-market ERP (assumed) | ~6.60% | Damodaran 2026 global |
| Levered β | 0.9191 | |
| Weighted CRP | 1.79% | country mix × per-country |
| Cost of equity | 7.93% | |
| Pre-tax cost of debt | 1.96% | synth rating Aaa/AAA |
| WACC | 7.70% | |
| Terminal growth | 2.40% | |
| Terminal ROIC | 15.00% |
Full year-by-year DCF
| Year | Revenue | Op mgn | EBIT | EBIT(1−t) | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | €5.89B | 7.4% | €437M | €311M | €76M | €235M | €218M |
| 2 | €6.13B | 7.5% | €459M | €326M | €79M | €247M | €213M |
| 3 | €6.37B | 7.6% | €481M | €342M | €82M | €260M | €208M |
| 4 | €6.63B | 7.6% | €505M | €358M | €85M | €273M | €203M |
| 5 | €6.89B | 7.7% | €529M | €376M | €88M | €287M | €198M |
| 6 | €7.17B | 7.7% | €555M | €393M | €92M | €301M | €193M |
| 7 | €7.45B | 7.8% | €582M | €411M | €96M | €315M | €188M |
| 8 | €7.75B | 7.9% | €610M | €430M | €99M | €330M | €182M |
| 9 | €8.06B | 7.9% | €640M | €449M | €103M | €346M | €177M |
| 10 | €8.38B | 8.0% | €671M | €470M | €107M | €362M | €172M |
Methodology & flags
Damodaran FCFF DCF, 10y explicit + perpetuity. R&D capitalisation: OFF · Lease capitalisation: OFF · Failure-rate adjustment: OFF · ESO subtraction: OFF.